Connect
MJA
MJA

Paracetamol should be first-line therapy in osteoarthritis

Richard O Day and Garry G Graham
Med J Aust 2005; 182 (4): 198-199.
Published online: 21 February 2005

Richard O Day,* Garry G Graham

  • Richard O Day
  • Garry G Graham

  • 1 University of New South Wales and St Vincent’s Hospital, Victoria Road, Darlinghurst, NSW 2010
  • 2 University of New South Wales, Sydney, NSW

Correspondence: 

Competing interests:

Professor Day is a member of advisory committees on COX-2 inhibitors for Merck Sharp & Dohme (Aust) Pty Ltd (which markets rofecoxib and etoricoxib), and previously for Pfizer Pty Ltd (which markets celecoxib). He is a member of a general advisory committee of GlaxoSmithKline (which markets paracetamol). GlaxoSmithKline have supported research projects of Professor Graham on paracetamol.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.